NCT03742193 (PROACH) is a Phase 2 clinical trial of Apatinib in Osteosarcoma, sponsored by Ruijin Hospital.

Who is sponsoring NCT03742193?

NCT03742193 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT03742193?

Interventions in NCT03742193: Apatinib, GD regimen.

What condition does NCT03742193 study?

NCT03742193 studies Osteosarcoma, Pulmonary Metastases, Apatinib.

Is NCT03742193 still recruiting?

NCT03742193 is currently status unknown. Last updated 1 November 2023.

Last reviewed 2023-11-01 · How we verify

NCT03742193: PROACH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

Status unknown Phase 2 Last updated 1 November 2023

What this trial tests

Phase 2 trial testing Apatinib in Osteosarcoma in 43 participants. Status unknown.

Timeline

11 August 2019

Primary endpoint
15 November 2023

30 December 2023

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	11 August 2019
Primary completion	15 November 2023
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →
GD regimen — full drug profile →

Conditions studied

Osteosarcoma — all drugs for Osteosarcoma →
Pulmonary Metastases — all drugs for Pulmonary Metastases →
Apatinib — all drugs for Apatinib →

Sponsor

Ruijin Hospital

Who can join

Adults 10 to 50, any sex, with Osteosarcoma or Pulmonary Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the efficacy and safety of Second-line chemotherapy combined with Apatinib for the patients with resectable pulmonary metastasis of osteosarcoma.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.
Harris MA, Hawkins CJ. · · 2022 · cited 100× · PMID 35409176 · DOI 10.3390/ijms23073817
Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.
Rathore R, Van Tine BA. · · 2021 · cited 81× · PMID 33809018 · DOI 10.3390/jcm10061182
Targeting the VEGF Pathway in Osteosarcoma.
Assi T, Watson S, Samra B, Rassy E, et al · · 2021 · cited 50× · PMID 34069999 · DOI 10.3390/cells10051240
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK, Yamamichi T, Yustein JT. · · 2023 · cited 32× · PMID 37511127 · DOI 10.3390/ijms241411367
Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.
Scotlandi K, Hattinger CM, Pellegrini E, Gambarotti M, et al · · 2020 · cited 25× · PMID 32295254 · DOI 10.3390/cells9040968
Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities.
Du X, Wei H, Zhang B, Wang B, et al · · 2023 · cited 23× · PMID 37197432 · DOI 10.3389/fonc.2023.1117867
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.
Just MA, Van Mater D, Wagner LM. · · 2021 · cited 23× · PMID 33894051 · DOI 10.1002/pbc.29084

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other recruiting trials for Osteosarcoma

Currently open trials in the same condition.

NCT07479732 — Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma · Phase 1, PHASE2 · recruiting
NCT06935409 — Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-li · Phase 3 · active not recruiting
NCT06521567 — A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · Phase 1, PHASE2 · active not recruiting
NCT06709495 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol · Phase 1, PHASE2 · recruiting
NCT06541262 — Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors · Phase 1, PHASE2 · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03742193 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 1 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03742193.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing